학술논문
Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins
Document Type
article
Author
Thomas Steimlé; Marie-Emilie Dourthe; Marion Alcantara; Aurore Touzart; Mathieu Simonin; Johanna Mondesir; Ludovic Lhermitte; Jonathan Bond; Carlos Graux; Nathalie Grardel; Jean-Michel Cayuela; Isabelle Arnoux; Virginie Gandemer; Marie Balsat; Norbert Vey; Elizabeth Macintyre; Norbert Ifrah; Hervé Dombret; Arnaud Petit; André Baruchel; Philippe Ruminy; Nicolas Boissel; Vahid Asnafi
Source
Blood Cancer Journal, Vol 12, Iss 1, Pp 1-8 (2022)
Subject
Language
English
ISSN
2044-5385
Abstract
Abstract T-cell acute lymphoblastic leukemias (T-ALL) represent 15% of pediatric and 25% of adult ALL. Since they have a particularly poor outcome in relapsed/refractory cases, identifying prognosis factors at diagnosis is crucial to adapting treatment for high-risk patients. Unlike acute myeloid leukemia and BCP ALL, chromosomal rearrangements leading to chimeric fusion-proteins with strong prognosis impact are sparsely reported in T-ALL. To address this issue an RT-MPLA assay was applied to a consecutive series of 522 adult and pediatric T-ALLs and identified a fusion transcript in 20% of cases. PICALM-MLLT10 (4%, n = 23), NUP214-ABL1 (3%, n = 19) and SET-NUP214 (3%, n = 18) were the most frequent. The clinico-biological characteristics linked to fusion transcripts in a subset of 235 patients (138 adults in the GRAALL2003/05 trials and 97 children from the FRALLE2000 trial) were analyzed to identify their prognosis impact. Patients with HOXA trans-deregulated T-ALLs with MLLT10, KMT2A and SET fusion transcripts (17%, 39/235) had a worse prognosis with a 5-year EFS of 35.7% vs 63.7% (HR = 1.63; p = 0.04) and a trend for a higher cumulative incidence of relapse (5-year CIR = 45.7% vs 25.2%, HR = 1.6; p = 0.11). Fusion transcripts status in T-ALL can be robustly identified by RT-MLPA, facilitating risk adapted treatment strategies for high-risk patients.